Alnylam Pharmaceuticals Announces Management Change

Jul 19,2004

Alnylam Pharmaceuticals Announces Management Change

CAMBRIDGE, Mass., July 19 /PRNewswire-FirstCall/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Thomas Ulich, M.D., Senior Vice President of Research and Development, has resigned from the Company effective July 30, 2004 to pursue other interests.

"We thank Tom for his important contributions to Alnylam's research effort over the past year and wish him the best," commented John Maraganore, Ph.D., chief executive officer of Alnylam.

"I believe that Alnylam is the pre-eminent company in the exciting field of RNA interference," stated Dr. Ulich. "I will miss the team there and look forward to following the Company's progress going forward."

About Alnylam

Alnylam is a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi therapeutics. Alnylam is developing a pipeline of RNAi products using Direct RNAi™ to treat ocular, central nervous system, and respiratory diseases and Systemic RNAi™ to treat a broad range of diseases, including oncologic, metabolic, and autoimmune diseases. The company's global headquarters are in Cambridge, Mass. For additional information, please visit

Alnylam Forward-Looking Statement
Statements in this release concerning our future expectations, plans and prospects, including statements regarding our ability to commercialize RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs is unproven and may never lead to marketable products, our ability to obtain additional funding to support our business activities, our dependence on third parties for development, manufacture, marketing, sales and distribution of our products, successfully developing any products, all of which are in early stages of development, obtaining regulatory approval for products, competition from using technology similar to ours and others developing products for similar uses, obtaining, maintaining and protecting intellectual property utilized by our products, our dependence on collaborators and our short operating history, as well as those risks more fully discussed in the "Risk Factors" section of the final prospectus relating to our initial public offering on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

SOURCE Alnylam Pharmaceuticals, Inc.

KMorris PR
Kathryn Morris
Stern Investor Relations, Inc.
Lilian Stern